FDA approves Pfizer's biosimilar ABRILADA adalimumabafzb for multiple inflammatory conditions

Pfizer Inc. NYSE PFE announced the United States U.S. Food and Drug Administration FDA has approved ABRILADA adalimumabafzb as a biosimilar to Humira adalimumab1 for the treatment of certain patients with rheumatoid arthritis juvenile idiopathic arthritis...